The company had been in the healthcare industry for around 3 decades. It produced a few lifesaving drugs and others related to general and specific diseases. With the rising attention towards the impact of chemicals on the environment and life and the serious side effects of some chemicals on humans, the demand for the drugs gradually started showing a decline. The company was facing allegations of introducing xenobiotics in the environment from its cancer drug production. The organization had other drugs too that were going through the same challenge and facing a dripping market share. The environmental impact of the wastewater produced from the chemicals used in drug manufacturing did not go down well with the government regulations. In the year 2016, the company had to pay USD 75,000 in civil penalty violations for its wastewater disposal. Apart from that, government penalties and fines dented the market reputation and position of the company. The shares fell initially -25% QoQ in 2014 and then approximately -45% YoY till 2017. The company was facing severe losses by the end of 2017 when it finally brought RNPL into its realm to figure out a life-saving strategy for the company. Research Nester offered a customized solution for Pharmaceutical & Biotechnology Environmental Monitoring analysis, which helped the organization in switching its product development from chemical to organically sustainable. The major areas that required focus as observed by Research Nester analysts were-